Fig. 5
From: Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer
In vitro cytotoxic assays of chemotherapy drugs combined with anti-HFG-induced CDC in DLD-1 and SW1116 cells. DLD-1 a, b and SW1116 c, d cells are treated with either vehicle, 5-FU plus oxaliplatin/irinotecan, or the combination of 5-FU plus oxaliplatin/irinotecan for 48 h followed by CDC induced by 100-μg/mL anti-HFG mAb for 4 h. Data are expressed as mean ± standard deviation of duplicates. CDC complement dependent cytotoxicity